Envestnet Asset Management Inc. lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 11.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,708 shares of the medical instruments supplier’s stock after selling 11,206 shares during the period. Envestnet Asset Management Inc.’s holdings in Becton, Dickinson and were worth $17,585,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in BDX. Almanack Investment Partners LLC. bought a new position in shares of Becton, Dickinson and in the first quarter valued at approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Becton, Dickinson and by 8.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after acquiring an additional 51 shares during the last quarter. Harfst & Associates Inc. lifted its holdings in shares of Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the last quarter. Finally, Financial Architects Inc lifted its holdings in shares of Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares during the last quarter. Institutional investors own 88.46% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded up $0.15 during midday trading on Wednesday, hitting $219.07. 963,700 shares of the company traded hands, compared to its average volume of 1,319,580. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $229.68. The stock has a market capitalization of $49,909.01, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.12 earnings per share. equities analysts predict that Becton, Dickinson and Company will post 10.63 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a dividend of $0.75 per share. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, December 7th. Becton, Dickinson and’s payout ratio is presently 62.80%.

A number of equities research analysts have recently weighed in on BDX shares. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Tuesday, October 31st. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Cowen reaffirmed a “buy” rating and issued a $230.00 target price on shares of Becton, Dickinson and in a research note on Monday, August 14th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $217.08.

In other Becton, Dickinson and news, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now directly owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Envestnet Asset Management Inc. Has $17.59 Million Stake in Becton, Dickinson and Company (BDX)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://theolympiareport.com/2017/12/06/envestnet-asset-management-inc-has-17-59-million-stake-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.